echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Shanghai Nanhai Pharmaceutical Co., Ltd., a controlling shareholder of 2 billion capital increase

    Shanghai Nanhai Pharmaceutical Co., Ltd., a controlling shareholder of 2 billion capital increase

    • Last Update: 2018-11-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    On November 16, Hainan Haiyao announced that Xinxing International Pharmaceutical Co., Ltd plans to gain control over Hainan Haiyao by means of cash capital increase in Nanfang Tongzheng, with the capital increase amount not exceeding 2 billion yuan It is understood that Xinxing International Pharmaceutical Co., Ltd is a wholly-owned subsidiary of Xinxing International Pharmaceutical Group, which is directly supervised by the SASAC of the State Council According to the agreement disclosed on December 16, the actual controller of Hainan Haiyao has acknowledged that he has made commitments to the future product listing and R & D Progress of Hainan Haiyao: Shanghai lisengte Medical Technology Co., Ltd., which is held by Hainan Haiyao, will complete the registration and listing of the second generation cochlear implant system products by December 31, 2020; China antibody Pharmaceutical Co., Ltd., which is invested by Hainan Haiyao, will By December 31, 2020, at least one new monoclonal antibody class 1 drug product will be approved for listing, and by the end of 2019, China antibody Pharmaceutical Co., Ltd will be listed; Shanghai youcadi Biomedical Technology Co., Ltd., which promises to invest in Hainan Haiyao, will have at least two new chimeric antigen receptor T-cell therapy (car-t) class 1 drug products obtained clinical approval documents by December 31, 2019 In addition, according to the 2018 semi annual report of Hainan Haiyao, the company realized operating revenue of RMB 1.153 billion in the first half of the year, a year-on-year increase of 51.06%; net profit attributable to shareholders of listed companies was RMB 150 million, a year-on-year increase of 31.61% The following is the full text of the announcement:
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.